Archiv
Archiv anzeigen:
bis


Adverse Effects of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Brady L. Stein, MD, MHS reviewing Jain P et al. Blood Adv 2019 Mar 26

Type of TKI is associated with increased risk for cardiovascular and arteriothrombotic events.


Are Tumor-Infiltrating Lymphocytes Prognostic in Triple-Negative Breast Cancer?

William J. Gradishar, MD reviewing Loi S et al. J Clin Oncol 2019 Mar 1

The percentage of stromal TILs in the tumor environment was associated with improved disease-free and overall survival.


Predicting Efficacy of Adjuvant Tamoxifen for Early-Stage Breast Cancer

William J. Gradishar, MD reviewing Sanchez-Spitman A et al. J Clin Oncol 2019 Mar 10

Neither a patient's CPY2D6 status nor endoxifen concentration affected relapse-free survival.


Is Flu Vaccine Safe for Cancer Patients Receiving Immune Checkpoint Inhibitors?

Stephen G. Baum, MD reviewing Chong CR et al. Clin Infect Dis 2019 Mar 15

Inactivated influenza vaccine does not provoke untoward immune reactions in these patients.


Vitamin K to Reverse Excessive VKA Anticoagulation

Brady L. Stein, MD, MHS reviewing Khatib R et al. Blood Adv 2019 Mar 12

Beyond holding anticoagulation, adding vitamin K did not reduce mortality, bleeding, or thrombosis risks in nonbleeding patients with elevated INRs.


Risk for Basal Cell Carcinoma Is Greatly Increased in Childhood Cancer Survivors

F. Bruder Stapleton, MD reviewing Teepen JC et al. J Natl Cancer Inst 2019 Feb 25

Childhood survivors who received radiotherapy had a 30-fold increase in the incidence of basal cell carcinoma.


Adjuvant Gemcitabine and Oxaliplatin for Resected Biliary Cancer

David H. Ilson, MD, PhD reviewing Edeline J et al. J Clin Oncol 2019 Mar 10

The combination failed to improve survival versus observation.


Complement Inhibition for Hemolytic Anemia in Cold Agglutinin Disease

Brady L. Stein, MD, MHS reviewing Jäger U et al. Blood 2019 Feb 28

Sutimlimab, an anti-C1s antibody, was well tolerated and rapidly improved hemoglobin.


Arterial Thrombosis and Occult Cancer

Brady L. Stein, MD, MHS reviewing Navi BB et al. Blood 2019 Feb 21

Cancer patients had significantly increased risk for arterial thrombosis in the year before cancer diagnosis.


The 2019 Gastrointestinal Cancers Symposium

David H. Ilson, MD, PhD

Highlights of the latest GI cancer trials


Archiv
Seite von 81
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Maintenance Immunotherapy for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Le Gouill S et al. N Engl J Med 2017 Sep 28

The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.


Adding Lorazepam to Haloperidol Might Help Alleviate Agitated Delirium in Advanced-Cancer Patients

Thomas L. Schwenk, MD reviewing Hui D et al. JAMA 2017 Sep 19, Pandharipande PP and Ely EW. JAMA 2017 Sep 19

Short-term reductions in agitation were helpful, but other components of delirium need further study.


Consolidation Immunotherapy After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2017 Sep 8

Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.


Axillary Dissection Unnecessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes

Henry Mark Kuerer, MD, PhD, FACS reviewing Giuliano AE et al. JAMA 2017 Sep 12, Livingston EH and Li HC. JAMA 2017 Sep 12

Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.


Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma

David H. Ilson, MD, PhD reviewing Alderson D et al. Lancet Oncol 2017 Sep

More intense preoperative chemotherapy fails to improve survival.


Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer

David H. Ilson, MD, PhD reviewing Overman MJ et al. Lancet Oncol 2017 Sep

The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.


Does Cutting Dietary Fat Affect Breast Cancer Outcomes?

Andrew M. Kaunitz, MD reviewing Chlebowski RT et al. J Clin Oncol 2017 Sep 1

Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.


Prothrombin Complex Concentrate for Bleeding from Direct Oral Anticoagulants

David Green, MD, PhD reviewing Majeed A et al. Blood 2017 Aug 23

Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.


Lung Cancer Rates Are Increasing Among Never-Smokers

Anne S. Tsao, MD reviewing Pelosof L et al. J Natl Cancer Inst 2017 Jul

From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.


Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer

William J. Gradishar, MD reviewing Ma CX et al. Clin Cancer Res 2017 Aug 1

Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.